In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling

Cancer Research

Volumn 70, Issue 8, 2010, Pages 3209-3217

  De Haij, Simone ^a   Jansen, J H Marco ^a   Boross, Peter ^a   Beurskens, Frank J ^a   Bakema, Jantine E ^a   Bos, Desiree L ^a   Martens, Anton ^a   Verbeek, J Sjef ^b   Parren, Paul W H I ^a   Van De Winkel, Jan G J ^a   Leusen, Jeanette H W ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD20 ANTIBODY; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR; GP75 ANTIGEN; OFATUMUMAB; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CONTROLLED STUDY; CROSS LINKING; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPHOMA; MOUSE; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; APOPTOSIS; HUMANS; IMMUNOTHERAPY; MELANOMA, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, FC; SEQUENCE HOMOLOGY, AMINO ACID; SIGNAL TRANSDUCTION;

EID: 77951084957     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4109     Document Type: Article

References (45)

1. Parren PW, van de Winkel JG. An integrated science-based approach to drug development. Curr Opin Immunol 2008;20:426-430
2. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-446
3. Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcaγRIIIa gene. Blood 2002;99:754-758 (Pubitemid 34525533)
4. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007;449:101-104 (Pubitemid 47373775)
5. Nimmerjahn F, Ravetch JV. Fcγ receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34-47.
6. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-3947 (Pubitemid 46606207)
7. Zhang W, Gordon M, Schultheis AM, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007;25:3712-3718 (Pubitemid 47372612)
8. Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-1796
9. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 1998;95:652-656 (Pubitemid 28083798)
10. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002;107:176-182 (Pubitemid 35279043)
11. Brodowicz T, Kandioler D, Tomek S, et al. Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status. Br J Cancer 2001;85:1764-1770 (Pubitemid 34081525)
12. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91:1644-1652 (Pubitemid 28110329)
13. Ghetie MA, Bright H, Vitetta ES. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood 2001;97:1392-1398 (Pubitemid 32183764)
14. Li B, Shi S, Qian W, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res 2008;68:2400-2408 (Pubitemid 351521815)
15. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-174
16. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002;99:1038-1043 (Pubitemid 34525569)
17. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcRγ chain deletion results in pleiotrophic effector cell defects. Cell 1994;76:519-529 (Pubitemid 24064172)
18. Brini AT, Lee GM, Kinet JP. Involvement of Alu sequences in the cell-specific regulation of transcription of the γ chain of Fc and T cell receptors. J Biol Chem 1993;268:1355-1361
19. Kuster H, Thompson H, Kinet JP. Characterization and expression of the gene for the human Fc receptor γ subunit. Definition of a new gene family. J Biol Chem 1990;265:6448-6452 (Pubitemid 20148196)
20. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003;171:1581-1587 (Pubitemid 36900094)
21. Mocsai A, Abram CL, Jakus Z, Hu Y, Lanier LL, Lowell CA. Integrin signaling in neutrophils and macrophages uses adaptors containing immunoreceptor tyrosine-based activation motifs. Nat Immunol 2006;7:1326-1333 (Pubitemid 46111254)
22. Bevaart L, van Ojik HH, Sun AW, et al. CpG oligodeoxynucleotides enhance FcγRI-mediated cross presentation by dendritic cells. Int Immunol 2004;16:1091-1098 (Pubitemid 39136726)
23. Tan AS, Berridge MV. Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents. J Immunol Methods 2000;238:59-68.
24. Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG, Leusen JH. The high-affinity IgG receptor, FcγRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res 2006;66:1261-1264 (Pubitemid 43259901)
25. van Lent P, Nabbe KC, Boross P, et al. The inhibitory receptor FcγRII reduces joint inflammation and destruction in experimental immune complex-mediated arthritides not only by inhibition of FcγRI/III but also by efficient clearance and endocytosis of immune complexes. Am J Pathol 2003;163:1839-1848 (Pubitemid 37310015)
26. Stockmeyer B, Beyer T, Neuhuber W, et al. Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. J Immunol 2003;171:5124-5129 (Pubitemid 37432795)
27. + B cell/macrophage IIA1.6 cells. Clin Exp Immunol 1998;113:415-422
28. van Vugt MJ, Kleijmeer MJ, Keler T, et al. The FcγRIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcRγ-chain. Blood 1999;94:808-817 (Pubitemid 29323896)
29. Sanchez-Mejorada G, Rosales C. Signal transduction by immunoglobulin Fc receptors. J Leukoc Biol 1998;63:521-533
30. van Spriel AB, van Ojik HH, Bakker A, Jansen MJ, van de Winkel JG. Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood 2003;101:253-258 (Pubitemid 36025915)
31. Minard-Colin V, Xiu Y, Poe JC, et al. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcγRI, FcγRIII, FcγRIV. Blood 2008;112:1205-1213
32. Uchida J, Hamaguchi Y, Oliver JA, et al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J Exp Med 2004;199:1659-1669 (Pubitemid 38821999)
33. Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcγ receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 2006;203:743-753
34. Setaluri V. Sorting and targeting of melanosomal membrane proteins: signals, pathways, and mechanisms. Pigment Cell Res 2000;13:128-134 (Pubitemid 30400276)
35. Nimmerjahn F, Ravetch JV. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 2005;310:1510-1512 (Pubitemid 41746349)
36. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002;99:1314-1319 (Pubitemid 34547086)
37. Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094-1100 (Pubitemid 351213387)
38. Osterborg A, Kipps TJ, Mayer J, et al. Ofatumumab (HuMax-CD20), a novel CD20 monoclonal antibody, is an active treatment for patients with CLL refractory to both fludarabine and alemtuzumab or bulky fludarabine-refractory disease: results from the planned interim analysis of an international pivotal trial [abstract 328]. Blood (ASH Annual Meeting Abstracts) 2008;112:328.
39. Sakurai D, Yamasaki S, Arase K, et al. FcεRIγ-ITAM is differentially required for mast cell function in vivo. J Immunol 2004;172:2374-2381 (Pubitemid 38182386)
40. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147-1157
41. Mir SS, Richter BW, Duckett CS. Differential effects of CD30 activation in anaplastic large cell lymphoma and Hodgkin disease cells. Blood 2000;96:4307-4312
42. Tiroch K, Stockmeyer B, Frank C, Valerius T. Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicity. J Immunol 2002;168:3275-3282 (Pubitemid 34250388)
43. Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-1800
44. Abram CL, Lowell CA. The expanding role for ITAM-based signaling pathways in immune cells. Sci STKE 2007;2007:re2.
45. Ivashkiv LB. Cross-regulation of signaling by ITAM-associated receptors. Nat Immunol 2009;10:340-347